


ALEXION, ASTRAZENECA RARE DISEASE UK & IRELAND



*INCLUDING MANUFACTURING
FACILITIES IN IRELAND

Our mission is to transform the lives of people living with rare diseases through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services

Our understanding of rare diseases began in our pioneering work
in complement biology

20+

Years of leadership in
complement-mediated
diseases

40,000

patient-years of trials and
real-world data in more
than 50 countries

FIRST PNH THERAPY

identified and researched
in the UK following
collaboration between leading
UK PNH clinicians and Alexion¹

Our innovation is driven by understanding people living
with rare diseases, which fuels all our efforts

3.5

million people
are affected by a
rare disease
in the UK²

Rare diseases are
often **severe**, chronic
and progressive, with
high mortality rates

52%

of patients initially
receive an **incorrect
diagnosis**³

95%

of rare diseases
do not have a
treatment available



Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology, and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.



ALEXION PHARMA UK LTD
Stockley Park, 3 Furzeground Way, Hayes, Uxbridge UB11 1EZ
Tel: +44 (0)20 8744 6600 Fax: +44 (0)20 8744 6630
Website: <https://alexion.com/worldwide/UK>

ALEXION. RARE INSPIRATION. CHANGING LIVES